Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir

AIDS

Volumn 19, Issue 13, 2005, Pages 1433-1434

  Bonfanti, Paolo ^a   Ricci, Elena ^a   Penco, Giovanni ^b   Orofino, Giancarlo ^c   Bini, Teresa ^a   Sfara, Claudio ^d   Miccolis, Sebastiano ^e   Cristina, Giovanni ^f   Quirino, Tiziana ^g  

^a UNIVERSITY OF MILAN   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

^d Sezione di Clin Malat Infettive   (Italy)

^e Divisione di Malattie Infettive   (Italy)

^f Divisione di Malattie Infettive   (Italy)

^g Divisione di Malattie Infettive   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL;

EID: 29144517548     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000180791.85003.3b     Document Type: Article

References (11)

1. Wit FWNM, Weverling GJ, Weel J, Jurrians S, Lange JMA. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
2. Puoti M, Torti C, Ripamonti D, and the HIV/HCV Co-infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32:259-267.
3. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30 (Suppl. 1):S77-S84.
4. Bonfanti P, Landonio S, Ricci E, Martinelli C, Fortuna P, Faggion I, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:316-318.
5. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
6. Hicks C, King MS, Gulick R, Clinton White A, Eron JJ, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4-year follow-up study. AIDS 2004; 18:775-779.
7. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277-2284.
8. Meraviglia P, Schiavini M, Castagna A, Vigano P, Bini T, Landonio S, et al. Lopinavir/ritonavir treatment in HIV antiretro viral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 2004; 5:334-343.
9. Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, et al. An Italian approach to post-marketing monitoring: preliminary results from the SCOLTA Project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr 2005; 39:317-320.
10. AIDS Clinical Trials Group. Table of grading severity of adult severe experiences. Rocksville: Division of AIDS, National Institute of Allergy and Infectious Diseases. 1996.
11. Gonzalez-Requena D, Nunez M, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C co-infection. AIDS Res Hum Retroviruses 2004; 20:698-700.